DS Healthcare CEO Daniel Khesin responded in a letter to recent calls about an article published by an anonymous author who calls himself "Bleecker Street Research," saying that the article was the "most shameless and deliberate attempt" to profit from a short position on a stock by the author himself and "possibly other parties that the author is affiliated with." Khesin wrote in the letter that the company does not claim to be "perfect" and has "many challenges" ahead, but that it does "work relentlessly to build value" for shareholders. The letter addressed each claim from Bleecker Street Research one by one, starting with the allegation that the company's 500% stock rise in 2015 was due to "overly promotional" press releases touting profitability as well as appearances on microcap promotion network. Khesin said that all of the information published in press releases is based on 100% factual statements and reviewed by auditors at Marcum. The letter also said that the recent "going concern" warning was nothing new and that the company is not, in fact, out of cash at hand. The letter also addresses falsehoods about the recent resignation of Mark Wolfson from the board and the notion that Khesin is the only person truly running the company. "We further note that in the article, Bleecker mentions that they have unsuccessful tried to reach investor relations," the letter reads. "We have never heard from anyone that we have not promptly responded to." Reference Link